411 related articles for article (PubMed ID: 33017914)
21. Combating sars-cov-2 through lipoxins, proteasome, caveolin and nuclear factor-κb pathways in non-pregnant and pregnant populations.
Celik O; Celik N; Aydin S; Baysal B; Aydin S; Saglam A; Gursu Y; Dalkilic S; Ulas M; Ozcil MD; Tayyar AT; Cengiz F; Ugur K; Akkoc RF; Ersahin AA
Cell Mol Biol (Noisy-le-grand); 2020 Jun; 66(3):221-229. PubMed ID: 32538775
[TBL] [Abstract][Full Text] [Related]
22. H
Yang G
Am J Physiol Cell Physiol; 2020 Aug; 319(2):C244-C249. PubMed ID: 32515982
[TBL] [Abstract][Full Text] [Related]
23. Perspectives on development of vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
Zhang C; Zhou C; Shi L; Liu G
Hum Vaccin Immunother; 2020 Oct; 16(10):2366-2369. PubMed ID: 32961082
[TBL] [Abstract][Full Text] [Related]
24. Identification of a Potential Peptide Inhibitor of SARS-CoV-2 Targeting its Entry into the Host Cells.
Baig MS; Alagumuthu M; Rajpoot S; Saqib U
Drugs R D; 2020 Sep; 20(3):161-169. PubMed ID: 32592145
[TBL] [Abstract][Full Text] [Related]
25. COVID-19/SARS-CoV-2 Infection: Lysosomes and Lysosomotropism Implicate New Treatment Strategies and Personal Risks.
Blaess M; Kaiser L; Sauer M; Csuk R; Deigner HP
Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32668803
[TBL] [Abstract][Full Text] [Related]
26. Learning from our immunological history: What can SARS-CoV teach us about SARS-CoV-2?
Henrickson SE
Sci Immunol; 2020 Apr; 5(46):. PubMed ID: 32245885
[TBL] [Abstract][Full Text] [Related]
27. Substituting Angiotensin-(1-7) to Prevent Lung Damage in SARS-CoV-2 Infection?
Peiró C; Moncada S
Circulation; 2020 May; 141(21):1665-1666. PubMed ID: 32242749
[No Abstract] [Full Text] [Related]
28. Synergistic antiviral effect of hydroxychloroquine and azithromycin in combination against SARS-CoV-2: What molecular dynamics studies of virus-host interactions reveal.
Fantini J; Chahinian H; Yahi N
Int J Antimicrob Agents; 2020 Aug; 56(2):106020. PubMed ID: 32405156
[TBL] [Abstract][Full Text] [Related]
29. Endocrine Significance of SARS-CoV-2's Reliance on ACE2.
Lazartigues E; Qadir MMF; Mauvais-Jarvis F
Endocrinology; 2020 Sep; 161(9):. PubMed ID: 32652001
[TBL] [Abstract][Full Text] [Related]
30. Endocrine aspects of ACE2 regulation: RAAS, steroid hormones and SARS-CoV-2.
Young MJ; Clyne CD; Chapman KE
J Endocrinol; 2020 Nov; 247(2):R45-R62. PubMed ID: 32966970
[TBL] [Abstract][Full Text] [Related]
31. Judicious use of sodium-glucose cotransporter 2 inhibitors in patients with diabetes on coronavirus-19 pandemic.
Chen CF; Chen YT; Chen TH; Chen FY; Yang YP; Wang ML; Huo TI; Chang YL; Charis Tan A; Lin CC
J Chin Med Assoc; 2020 Sep; 83(9):809-811. PubMed ID: 32433344
[TBL] [Abstract][Full Text] [Related]
32. Can dapagliflozin have a protective effect against COVID-19 infection? A hypothesis.
Cure E; Cumhur Cure M
Diabetes Metab Syndr; 2020; 14(4):405-406. PubMed ID: 32335366
[TBL] [Abstract][Full Text] [Related]
33. SARS-CoV-2 immunogenicity at the crossroads.
Karamloo F; König R
Allergy; 2020 Jul; 75(7):1822-1824. PubMed ID: 32401346
[No Abstract] [Full Text] [Related]
34. The ACE2 expression in human heart indicates new potential mechanism of heart injury among patients infected with SARS-CoV-2.
Chen L; Li X; Chen M; Feng Y; Xiong C
Cardiovasc Res; 2020 May; 116(6):1097-1100. PubMed ID: 32227090
[TBL] [Abstract][Full Text] [Related]
35. SARS-CoV-2 receptor ACE2-dependent implications on the cardiovascular system: From basic science to clinical implications.
Groß S; Jahn C; Cushman S; Bär C; Thum T
J Mol Cell Cardiol; 2020 Jul; 144():47-53. PubMed ID: 32360703
[TBL] [Abstract][Full Text] [Related]
36. Angiotensin Converting Enzyme-2 (ACE2) Receptors, asthma and severe COVID-19 infection risk.
Öztürk AB; Çağlayan B
Eur Ann Allergy Clin Immunol; 2020 Nov; 52(6):282-285. PubMed ID: 32914945
[No Abstract] [Full Text] [Related]
37. ACE2 imbalance as a key player for the poor outcomes in COVID-19 patients with age-related comorbidities - Role of gut microbiota dysbiosis.
Viana SD; Nunes S; Reis F
Ageing Res Rev; 2020 Sep; 62():101123. PubMed ID: 32683039
[TBL] [Abstract][Full Text] [Related]
38. Host Polymorphisms May Impact SARS-CoV-2 Infectivity.
Brest P; Refae S; Mograbi B; Hofman P; Milano G
Trends Genet; 2020 Nov; 36(11):813-815. PubMed ID: 32828550
[TBL] [Abstract][Full Text] [Related]
39. The SARS-CoV-2 Spike Glycoprotein as a Drug and Vaccine Target: Structural Insights into Its Complexes with ACE2 and Antibodies.
Papageorgiou AC; Mohsin I
Cells; 2020 Oct; 9(11):. PubMed ID: 33105869
[TBL] [Abstract][Full Text] [Related]
40. mRNA Vaccines: Possible Tools to Combat SARS-CoV-2.
Yi C; Yi Y; Li J
Virol Sin; 2020 Jun; 35(3):259-262. PubMed ID: 32524253
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
